Phase 3 Ovarian Cancer Trial, Recruiting NCT05737303 Sponsor: Women's Hospital School Of Medicine Zhejiang University Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 3 Ovarian Cancer Trial, Recruiting

NCT05737303
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with ovarian cancer, fallopian tube cancer, or peritoneal cancer (confirmed by a tissue or fluid sample), and it is classified as stage III or stage IV
  • Your general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard scoring system (score of 0–2 on the ECOG scale)
  • You have not taken part in another drug clinical trial in the 4 weeks before joining this study
  • You are willing and able to sign a written consent form agreeing to take part
  • You are expected to live for at least 6 months
  • Your cancer can be measured using standard imaging guidelines (called RECIST 1.1) to track whether treatment is working
  • You are able to attend outpatient appointments, have regular lab tests, and come to required clinic visits during the study

Who may not be able to join:

  • You have a type of ovarian tumour that is considered low-risk or "borderline" (low malignant potential)
  • You have had another cancer in the past 5 years, unless it was a fully cured early-stage cervical cancer or a non-melanoma skin cancer
  • You have previously had chemotherapy or radiation therapy in the pelvic area
  • You have cancer that has spread to the brain or spinal cord, or you have nerve damage beyond a mild level
  • You have seriously low blood cell counts, severe liver problems, or significant kidney problems at the time of screening
  • You have serious heart conditions, such as significant heart disease, a poorly controlled irregular heartbeat, recent heart attack, or poor heart pumping function (confirm with trial site for specific thresholds)
  • You have an active, uncontrolled infection that requires treatment
  • You have had a blood clot, stroke, mini-stroke, or heart attack in the 6 months before joining the trial
  • You are allergic to the study drugs (albumin-bound paclitaxel or carboplatin) or any of their ingredients
  • You are pregnant or currently breastfeeding
  • The study doctors have another reason they feel you would not be suitable for this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yaxia Chen, MD, Study Principal Investigator

Phone: +86-571-87061501

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Women's Hospital School Of Medicine Zhejiang University
Registry
ClinicalTrials.gov
Start date
27 November 2023
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression Free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov